2532 related articles for article (PubMed ID: 7620345)
1. p53 gene mutation and expression in naevi and melanomas.
Sparrow LE; Soong R; Dawkins HJ; Iacopetta BJ; Heenan PJ
Melanoma Res; 1995 Apr; 5(2):93-100. PubMed ID: 7620345
[TBL] [Abstract][Full Text] [Related]
2. Mutation and expression of the p53 gene in human malignant melanoma.
Albino AP; Vidal MJ; McNutt NS; Shea CR; Prieto VG; Nanus DM; Palmer JM; Hayward NK
Melanoma Res; 1994 Feb; 4(1):35-45. PubMed ID: 8032216
[TBL] [Abstract][Full Text] [Related]
3. p53 expression is rare in cutaneous melanomas.
Saenz-Santamaría MC; McNutt NS; Bogdany JK; Shea CR
Am J Dermatopathol; 1995 Aug; 17(4):344-9. PubMed ID: 8600797
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma.
Platz A; Ringborg U; Grafström E; Höög A; Lagerlöf B
Melanoma Res; 1995 Apr; 5(2):101-6. PubMed ID: 7620336
[TBL] [Abstract][Full Text] [Related]
5. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi.
Carr J; Mackie RM
Br J Dermatol; 1994 Jul; 131(1):72-7. PubMed ID: 8043423
[TBL] [Abstract][Full Text] [Related]
6. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
7. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.
Papp T; Jafari M; Schiffmann D
J Cancer Res Clin Oncol; 1996; 122(9):541-8. PubMed ID: 8781568
[TBL] [Abstract][Full Text] [Related]
8. p53 immunoreactivity in human malignant melanoma and dysplastic naevi.
McGregor JM; Yu CC; Dublin EA; Barnes DM; Levison DA; MacDonald DM
Br J Dermatol; 1993 Jun; 128(6):606-11. PubMed ID: 8338744
[TBL] [Abstract][Full Text] [Related]
9. High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
[TBL] [Abstract][Full Text] [Related]
10. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
11. Mutation and expression of TP53 in malignant melanomas.
Weiss J; Heine M; Arden KC; Körner B; Pilch H; Herbst RA; Jung EG
Recent Results Cancer Res; 1995; 139():137-54. PubMed ID: 7597286
[TBL] [Abstract][Full Text] [Related]
12. Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases.
Palmieri G; Ascierto PA; Cossu A; Colombino M; Casula M; Botti G; Lissia A; Tanda F; Castello G
Melanoma Res; 2003 Apr; 13(2):167-70. PubMed ID: 12690300
[TBL] [Abstract][Full Text] [Related]
13. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes.
Ragnarsson-Olding BK; Karsberg S; Platz A; Ringborg UK
Melanoma Res; 2002 Oct; 12(5):453-63. PubMed ID: 12394187
[TBL] [Abstract][Full Text] [Related]
15. Increased expression and mutation of p53 in choroidal melanoma.
Tobal K; Warren W; Cooper CS; McCartney A; Hungerford J; Lightman S
Br J Cancer; 1992 Nov; 66(5):900-4. PubMed ID: 1419633
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B
Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions.
Bergman R; Shemer A; Levy R; Friedman-Birnbaum R; Trau H; Lichtig C
Am J Dermatopathol; 1995 Dec; 17(6):547-50. PubMed ID: 8599466
[TBL] [Abstract][Full Text] [Related]
18. Absence of p53 gene mutations in cutaneous melanoma.
Lübbe J; Reichel M; Burg G; Kleihues P
J Invest Dermatol; 1994 May; 102(5):819-21. PubMed ID: 8176269
[TBL] [Abstract][Full Text] [Related]
19. P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach.
Schmitt FC; Soares R; Cirnes L; Seruca R
Pathol Res Pract; 1998; 194(12):815-9. PubMed ID: 9894246
[TBL] [Abstract][Full Text] [Related]
20. [Detection of point mutation of p53 gene by silver staining PCR-SSCP in paraffin-embedded malignant fibrous histiocytoma].
Li J; Yang G; Li G
Zhonghua Zhong Liu Za Zhi; 1996 Jan; 18(1):13-5. PubMed ID: 8732103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
